AXGN vs. ZYXI, CUTR, NTUS, ESTA, AORT, MDXG, EYE, BLFS, SILK, and AVNS
Should you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Zynex (ZYXI), Cutera (CUTR), Natus Medical (NTUS), Establishment Labs (ESTA), Artivion (AORT), MiMedx Group (MDXG), National Vision (EYE), BioLife Solutions (BLFS), Silk Road Medical (SILK), and Avanos Medical (AVNS).
AxoGen (NASDAQ:AXGN) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.
AxoGen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Zynex has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.
AxoGen received 422 more outperform votes than Zynex when rated by MarketBeat users. Likewise, 72.56% of users gave AxoGen an outperform vote while only 54.35% of users gave Zynex an outperform vote.
80.3% of AxoGen shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 7.0% of AxoGen shares are owned by insiders. Comparatively, 52.1% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Zynex has a net margin of 3.12% compared to AxoGen's net margin of -12.99%. Zynex's return on equity of 13.14% beat AxoGen's return on equity.
Zynex has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.
AxoGen currently has a consensus target price of $12.25, indicating a potential upside of 32.58%. Zynex has a consensus target price of $14.00, indicating a potential upside of 56.77%. Given Zynex's higher possible upside, analysts clearly believe Zynex is more favorable than AxoGen.
In the previous week, Zynex had 14 more articles in the media than AxoGen. MarketBeat recorded 18 mentions for Zynex and 4 mentions for AxoGen. AxoGen's average media sentiment score of 0.49 beat Zynex's score of -0.36 indicating that AxoGen is being referred to more favorably in the media.
Summary
Zynex beats AxoGen on 10 of the 17 factors compared between the two stocks.
Get AxoGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
